(audio-EN) DNA-based therapeutics: enGene successfuly raises CAD $13.5 million

Montreal (Quebec) – enGene, a Montreal-based biotechnology company, has just raised CAD $13.5 million in a Series B investment round led by Forbion Capital Partners, with participation of Lumira Capital and new investors Quebec’s Fonds de solidarité FTQ and Pharmstandard International. Inventor of a disruptive technology based on the idea of turning the gut into a protein factory by delivering DNA-based therapeutics, enGene has developed a drug candidate called EG-12 for the treatment of ulcerative colitis. Anthony Cheung, President and CEO of enGene, explains why he succeeded in the fundraising and the mechanism of action of its lead product, and also draws a brief picture of existing competitors. An exciting introduction to gastrointestinal tract-linked innovations, which will carry most of the progress in medicine in the coming years.